Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1970 1
1972 1
1995 1
1996 1
1997 1
1998 2
1999 1
2001 1
2002 3
2003 3
2004 2
2005 1
2006 4
2007 8
2008 8
2009 9
2010 8
2011 14
2012 13
2013 13
2014 12
2015 14
2016 18
2017 15
2018 17
2019 10
2020 11
2021 15
2022 10
2023 14
2024 28
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation.
Uojima H, Yamasaki K, Sugiyama M, Kage M, Ishii N, Shirabe K, Hidaka H, Kusano C, Murakawa M, Asahina Y, Nishimura T, Iijima H, Sakamoto K, Ito K, Amano K, Kawaguchi T, Tamaki N, Kurosaki M, Suzuki T, Matsuura K, Taketomi A, Joshita S, Umemura T, Nishina S, Hino K, Toyoda H, Yatsuhashi H, Mizokami M. Uojima H, et al. Among authors: nishina s. J Gastroenterol. 2024 Jul;59(7):598-608. doi: 10.1007/s00535-024-02100-3. Epub 2024 Apr 16. J Gastroenterol. 2024. PMID: 38625546
Iron and liver cancer: an inseparable connection.
Hino K, Yanatori I, Hara Y, Nishina S. Hino K, et al. Among authors: nishina s. FEBS J. 2022 Dec;289(24):7810-7829. doi: 10.1111/febs.16208. Epub 2021 Oct 14. FEBS J. 2022. PMID: 34543507 Free article. Review.
CCL22 mutations in large granular lymphocytic leukemia.
Mizuno Y, Kawakami T, Higano D, Miyairi S, Asakura A, Kawakami F, Sato K, Matsuzawa S, Nishina S, Sakai H, Higuchi Y, Matsuda K, Nakazawa H, Ishida F. Mizuno Y, et al. Among authors: nishina s. Haematologica. 2024 Sep 1;109(9):3067-3070. doi: 10.3324/haematol.2024.285404. Haematologica. 2024. PMID: 38813714 Free PMC article. No abstract available.
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T. Shimose S, et al. Among authors: nishina s. Oncol Lett. 2024 Jun 25;28(2):397. doi: 10.3892/ol.2024.14530. eCollection 2024 Aug. Oncol Lett. 2024. PMID: 38979550 Free PMC article.
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group. Saeki I, et al. Among authors: nishina s. PLoS One. 2024 Sep 25;19(9):e0311084. doi: 10.1371/journal.pone.0311084. eCollection 2024. PLoS One. 2024. PMID: 39321197 Free PMC article.
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
Kito Y, Kawakami H, Mitani S, Nishina S, Matsumoto T, Tsuzuki T, Shinohara Y, Shimokawa H, Kumanishi R, Ohta T, Katsuya H, Kawakami T, Nishina T, Hasegawa H, Akiyoshi K, Chiba Y, Yamazaki K, Hironaka S, Muro K. Kito Y, et al. Among authors: nishina s. Oncologist. 2024 Mar 4;29(3):e330-e336. doi: 10.1093/oncolo/oyad296. Oncologist. 2024. PMID: 37950903 Free PMC article.
230 results